792 related articles for article (PubMed ID: 18998069)
21. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
Nakanishi Y; Saxena R
Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
[TBL] [Abstract][Full Text] [Related]
22. New insights into autoimmune cholangitis through animal models.
Trauner M; Fickert P; Baghdasaryan A; Claudel T; Halilbasic E; Moustafa T; Wagner M; Zollner G
Dig Dis; 2010; 28(1):99-104. PubMed ID: 20460897
[TBL] [Abstract][Full Text] [Related]
23. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
24. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
25. Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma.
Scheimann AO; Strautnieks SS; Knisely AS; Byrne JA; Thompson RJ; Finegold MJ
J Pediatr; 2007 May; 150(5):556-9. PubMed ID: 17452236
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
27. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
28. Bile secretory failure: recent concepts of the pathogenesis of intrahepatic cholestasis.
Simon FR; Reichen J
Prog Liver Dis; 1982; 7():195-206. PubMed ID: 7051146
[No Abstract] [Full Text] [Related]
29. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
30. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
31. The pathophysiology of cholestasis with special reference to primary biliary cirrhosis.
Jansen PL
Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):571-83. PubMed ID: 10976015
[TBL] [Abstract][Full Text] [Related]
32. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
33. The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.
Li X; Liu R; Yang J; Sun L; Zhang L; Jiang Z; Puri P; Gurley EC; Lai G; Tang Y; Huang Z; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Sep; 66(3):869-884. PubMed ID: 28271527
[TBL] [Abstract][Full Text] [Related]
34. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice.
Hoekstra H; Porte RJ; Tian Y; Jochum W; Stieger B; Moritz W; Slooff MJ; Graf R; Clavien PA
Hepatology; 2006 May; 43(5):1022-31. PubMed ID: 16628673
[TBL] [Abstract][Full Text] [Related]
35. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
36. Macrophages in cholangiopathies.
Bruneau A; Guillot A; Tacke F
Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
[TBL] [Abstract][Full Text] [Related]
37. ABCB4 disease: Many faces of one gene deficiency.
Sticova E; Jirsa M
Ann Hepatol; 2020; 19(2):126-133. PubMed ID: 31759867
[TBL] [Abstract][Full Text] [Related]
38. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Fuchsbichler A; Wagner M; Zollner G; Kaser A; Tilg H; Krause R; Lammert F; Langner C; Zatloukal K; Marschall HU; Denk H; Trauner M
Gastroenterology; 2004 Jul; 127(1):261-74. PubMed ID: 15236191
[TBL] [Abstract][Full Text] [Related]
39. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
40. Destructive intrahepatic bile duct diseases.
Desmet VJ
Recenti Prog Med; 1990 Jun; 81(6):392-8. PubMed ID: 2251446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
